PDCD1 and non-small cell lung carcinoma: Keynote 021 is the first trial to publish a benefit of immune checkpoint inhibition with a PD-1 inhibitor in combination with chemotherapy over chemotherapy alone, in this case as first-line treatment for patients with non-small-cell lung cancer (NSCLC).